Similar risk of complete revision for infection with single-dose versus multiple-dose antibiotic prophylaxis in primary arthroplasty of the hip and knee: results of an observational cohort study in the Dutch Arthroplasty Register in 242,179 patients.


Journal

Acta orthopaedica
ISSN: 1745-3682
Titre abrégé: Acta Orthop
Pays: Sweden
ID NLM: 101231512

Informations de publication

Date de publication:
12 2020
Historique:
pubmed: 24 7 2020
medline: 11 2 2021
entrez: 24 7 2020
Statut: ppublish

Résumé

Background and purpose - The optimal type and duration of antibiotic prophylaxis for primary arthroplasty of the hip and knee are subject to debate. We compared the risk of complete revision (obtained by a 1- or 2-stage procedure) for periprosthetic joint infection (PJI) after primary total hip or knee arthroplasty between patients receiving a single dose of prophylactic antibiotics and patients receiving multiple doses of antibiotics for prevention of PJI. Patients and methods - A cohort of 130,712 primary total hip and 111,467 knee arthroplasties performed between 2011 and 2015 in the Netherlands was analyzed. We linked data from the Dutch arthroplasty register to a survey collected across all Dutch institutions on hospital-level antibiotic prophylaxis policy. We used restricted cubic spline Poisson models adjusted for hospital clustering to compare the risk of revision for infection according to type and duration of antibiotic prophylaxis received. Results - For total hip arthroplasties, the rates of revision for infection were 31/10,000 person-years (95% CI 28-35), 39 (25-59), and 23 (15-34) in the groups that received multiple doses of cefazolin, multiple doses of cefuroxime, and a single dose of cefazolin, respectively. The rates for knee arthroplasties were 27/10,000 person-years (95% CI 24-31), 40 (24-62), and 24 (16-36). Similar risk of complete revision for infection among antibiotic prophylaxis regimens was found when adjusting for confounders. Interpretation - In a large observational cohort we found no apparent association between the type or duration of antibiotic prophylaxis and the risk of complete revision for infection. This does question whether there is any advantage to the use of prolonged antibiotic prophylaxis beyond a single dose.

Identifiants

pubmed: 32698642
doi: 10.1080/17453674.2020.1794096
pmc: PMC8023957
doi:

Substances chimiques

Anti-Bacterial Agents 0
Cefazolin IHS69L0Y4T
Cefuroxime O1R9FJ93ED

Banques de données

ClinicalTrials.gov
['NCT03348254']

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

794-800

Références

Orthop Rev. 1989 Jun;18(6):694-6
pubmed: 2664670
Acta Orthop Scand. 2003 Dec;74(6):644-51
pubmed: 14763692
J Arthroplasty. 2014 Feb;29(2 Suppl):77-83
pubmed: 24342275
Lancet Infect Dis. 2018 Sep;18(9):1004-1014
pubmed: 30056097
JAMA Surg. 2017 Aug 01;152(8):784-791
pubmed: 28467526
Acta Orthop. 2015;86(4):498-505
pubmed: 25758646
J Bone Joint Surg Am. 2010 Sep 1;92(11):e13
pubmed: 20810849
J Bone Joint Surg Am. 2014 Apr 16;96(8):624-30
pubmed: 24740658
BMJ Open. 2015 Dec 07;5(12):e009495
pubmed: 26644124
Acta Orthop. 2012 Oct;83(5):449-58
pubmed: 23083433
Int J Antimicrob Agents. 2009 May;33(5):437-40
pubmed: 19117731
J Bone Joint Surg Am. 2013 Dec 18;95(24):2177-84
pubmed: 24352771
Ned Tijdschr Geneeskd. 2009;153:B39
pubmed: 19818192
Bone Joint Res. 2017 Jun;6(6):391-398
pubmed: 28642256
J Bone Joint Surg Br. 2008 Jul;90(7):915-9
pubmed: 18591602
J Bone Jt Infect. 2018 Jan 1;3(1):5-9
pubmed: 29291158
Clin Orthop Relat Res. 1986 Apr;(205):184-7
pubmed: 3698375
J Bone Joint Surg Am. 2015 Sep 2;97(17):1386-97
pubmed: 26333733
J Bone Joint Surg Am. 2019 Mar 6;101(5):429-437
pubmed: 30845037
Acta Orthop. 2015 Jun;86(3):326-34
pubmed: 25637247
Bone Joint J. 2019 Jun;101-B(6_Supple_B):9-15
pubmed: 31146571
CMAJ Open. 2015 Jul 17;3(3):E338-43
pubmed: 26457293
BMJ Open. 2017 Jul 10;7(7):e014056
pubmed: 28698316
Bone Joint Res. 2015 Nov;4(11):181-9
pubmed: 26585304
Clin Orthop Relat Res. 2020 Jun;478(6):1348-1355
pubmed: 32106134
J Bone Joint Surg Br. 2003 Sep;85(7):956-9
pubmed: 14516026
Acta Orthop. 2009 Dec;80(6):633-8
pubmed: 19995312
Ann Surg. 2009 Jul;250(1):10-6
pubmed: 19561486
J Bone Joint Surg Am. 2013 Apr 17;95(8):e50
pubmed: 23595076
Acta Orthop Scand. 1992 Feb;63(1):19-24
pubmed: 1738963
J Orthop Res. 2014 Jan;32 Suppl 1:S31-59
pubmed: 24464896
Am J Public Health. 2016 Aug;106(8):1388-9
pubmed: 27400352
J Infect. 2018 Dec;77(6):479-488
pubmed: 30205122
Arthroplast Today. 2018 Feb 14;4(1):130-131
pubmed: 29560408
Eur J Epidemiol. 2018 Oct;33(10):933-946
pubmed: 29623671

Auteurs

Ewout S Veltman (ES)

Department of Orthopaedic and Trauma Surgery, Joint Research, OLVG, Amsterdam, the Netherlands.
Department of Orthopaedics, Leiden University Medical Center, Leiden, the Netherlands.

Erik Lenguerrand (E)

3Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Dirk Jan F Moojen (DJF)

Department of Orthopaedic and Trauma Surgery, Joint Research, OLVG, Amsterdam, the Netherlands.

Michael R Whitehouse (MR)

3Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
National Institute for Health Research Bristol Biomedical Research Centre, University Hospital Bristol NHS Foundation Trust and University of Bristol, UK.

Rob G H H Nelissen (RGHH)

Department of Orthopaedics, Leiden University Medical Center, Leiden, the Netherlands.

Ashley W Blom (AW)

3Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
National Institute for Health Research Bristol Biomedical Research Centre, University Hospital Bristol NHS Foundation Trust and University of Bristol, UK.

Rudolf W Poolman (RW)

Department of Orthopaedic and Trauma Surgery, Joint Research, OLVG, Amsterdam, the Netherlands.
Department of Orthopaedics, Leiden University Medical Center, Leiden, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH